Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Hematology
Disease Category: Anemia

Trial Information

Pilot Study of Epoetin Alfa in Idiopathic Anemia of Aging (IAA). This is a study that is evaluating a drug referred to as Epoetin Alfa (erythropoietin) for treatment in people with anemia of unknown cause associated with advancing age.

As individuals become older, the frequency of anemia increases. While the cause of anemia in many cases can be determined and corrected, in a number of individuals there is no correctable cause found and the patient must live with their anemia. This is known as idiopathic anemia, and can have serious consequences for the individual. Numerous studies have demonstrated that anemia is associated with loss of energy and stamina, causing individuals to decrease their activities, which adversely affects both their sense of well-being as well as their physical strength. Losses in these areas are associated with the clinical manifestations of frailty.

The current pilot study will examine whether or not administration of Epoetin Alfa, a hormone stimulating production of red blood cells, can reverse this type of anemia. We will examine the consequences of reversing the anemia in terms of physical strength and function, cardiovascular function and sense of well-being and mental function.

In this study, individuals with anemia will be treated for six months with Epoetin Alfa following the correction of their anemia and measurements done to evaluate physical strength, performance, cardiac, mental and kidney function. At the end of treatment, individuals will be followed for an additional six months to determine whether the anemia recurs and physical function decreases.

Participation in this study is voluntary. All testing and medication received are free to the participant.

ELIGIBILITY

Men and women

Inclusion Criteria:

• 70 years of age or older
• Diagnosed with anemia
• Hemoglobin level less than or equal to 11
• Able to perform most activities of daily
  • living without restriction

Exclusion Criteria:

• History of serious heart, liver or kidney disease
• Cancer treated within the last year except for skin cancer (excluding melanoma)
• Problems with your immune system
• Received Epoetin Alfa within the last year

For more information,

National Institute on Aging
3001 S. Hanover Street, 5th Floor
Baltimore, MD 21225
Phone: 410-350-3941
EMail: NIAStudiesRecruitment@grc.nia.nih.gov

View Google Map

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.